Our end-goal is to improve patients’ quality of life with our innovative cardiac regenerative technology.

We believe major breakthroughs that improve patient outcomes are achieved through multidisciplinary collaborations.

This is why we have selected partners, advisors and investors who combine their expertise to make regeneration a new paradigm in cardiology with a relentless focus on quality and efficiency.


Current Support for Regencor includes  SBIR funding from the Department of Health and Human Services, NIH.


Nodes Advisors are a corporate finance firm committed to advancing the field of Life Sciences through advisory and capital raise.


Regencor and Phosphorex, a drug formulation and delivery company, have executed a collaboration agreement to develop Q-Beads, a subcutaneous sustained release formulation of Regencor's proprietary recombinant human protein for the regeneration of heart tissue after myocardial infarction.

Luina Bio is an Australian contract drug development manufacturing organization that has served the global biopharmaceutical industry for more than 20 years. Luina Bio will produce GMP-grade non-glycosylated FSTL1 for Regencor’s clinical trial program.

contract research organization

A global clinical CRO, CNS is an integrated service group focused on clinical product development, clinical trial design, execution and monitoring, biometrics, and regulatory compliance. CNS, with over 150 employees and 20+ years expertise, will support Regenor’s initial clinical trial program in Australia.